Gamma Globulin

Gamma Globulin Market Outlook

The global gamma globulin market is projected to reach approximately USD 15 billion by 2035, with a compound annual growth rate (CAGR) of around 8% from 2025 to 2035. The increasing prevalence of immunodeficiency disorders, coupled with rising healthcare awareness and advancements in biotechnology, is a primary driver fueling market growth. Additionally, the growing demand for immunotherapies and the rising number of product approvals from regulatory authorities are contributing positively to the market dynamics. The COVID-19 pandemic has further highlighted the importance of immune therapies, thereby enhancing the focus on gamma globulin products. Furthermore, an increasing geriatric population is also expected to play a vital role in the market's expansion.

Growth Factor of the Market

One of the significant growth factors propelling the gamma globulin market is the heightened prevalence of autoimmune and inflammatory diseases, which necessitate effective therapeutic interventions. As healthcare systems worldwide adapt to cope with chronic health conditions, gamma globulin is increasingly recognized for its therapeutic benefits in improving immune response and providing passive immunity. Furthermore, the rise in the awareness of rare diseases has prompted research and development in gamma globulin therapies, leading to innovative product launches. The expanding applications of gamma globulin in treating diseases like Chronic Inflammatory Demyelinating Polyneuropathy and Immune Thrombocytopenic Purpura have broadened the scope of the market as healthcare providers seek more effective treatment options. Additionally, advancements in manufacturing processes that enhance the yield and purity of immunoglobulin products are also a contributing factor to market growth.

Key Highlights of the Market

• The gamma globulin market is expected to experience robust growth due to increasing incidences of immunodeficiency disorders.
• Technological advancements in immunoglobulin production processes are improving product efficacy and safety.
• Healthcare initiatives focusing on enhancing patient education regarding immune therapies are driving market expansion.
• The emergence of online pharmacies is increasing the accessibility of gamma globulin products to patients.
• Regional markets, particularly in North America and Europe, are likely to dominate due to higher healthcare expenditure and better healthcare infrastructure.

By Product Type

Immune Globulin Intravenous (IGIV)

Immune Globulin Intravenous (IGIV) is one of the primary types of gamma globulin products available in the market. It is predominantly used to treat various autoimmune and immunodeficiency disorders, offering a concentrated dose of antibodies directly into the bloodstream. The administration of IGIV is typically performed in hospital settings due to the need for monitoring during the infusion process. The demand for IGIV has been on the rise, driven by increasing diagnoses of primary immunodeficiency diseases and the growing awareness among healthcare professionals regarding its therapeutic potential. Moreover, recent advancements in product development have led to the introduction of IGIV formulations with improved safety profiles and fewer side effects, further boosting its acceptance in clinical settings.

Immune Globulin Subcutaneous (IGSC)

Immune Globulin Subcutaneous (IGSC) has gained significant traction over the past few years due to its ease of administration and patient convenience. Unlike IGIV, which requires intravenous infusion, IGSC can be administered subcutaneously, allowing patients to self-administer treatments at home. This has enhanced patient compliance and satisfaction, making IGSC a preferred choice for many individuals, particularly those with chronic conditions requiring lifelong therapy. The growth in the IGSC segment is also attributable to the expanding indications for its use, including chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenic purpura. The convenience of subcutaneous administration, coupled with ongoing research into its efficacy for various conditions, positions IGSC as a promising product type in the gamma globulin market.

Hyperimmune Globulin

Hyperimmune globulin products are specialized immunoglobulins that are enriched with antibodies against specific pathogens, making them particularly effective in treating infections. This product type has seen growing demand due to its application in post-exposure prophylaxis and treatment for specific diseases, such as hepatitis and rabies. Hyperimmune globulin is procured from donors who have high antibody levels, and its targeted nature allows for effective therapeutic intervention. The ongoing research into additional applications for hyperimmune globulin is expected to drive future growth in this segment. Furthermore, the rising awareness of the benefits of hyperimmune globulins in infectious disease management is enhancing their market presence and acceptance among healthcare providers.

By Application

Primary Immunodeficiency

Primary immunodeficiency disorders represent a key application area for gamma globulin products, as these conditions result from intrinsic defects in the immune system. The use of immune globulin therapies is critical for managing these disorders, as they help restore immune function by providing essential antibodies. The increasing incidence of primary immunodeficiency conditions, coupled with advancements in genetic screening and diagnosis, has led to a surge in the demand for gamma globulin treatments. Healthcare providers are increasingly recognizing the importance of timely intervention with immunoglobulin therapies, which has resulted in improved patient outcomes and a growing market for gamma globulin products tailored to primary immunodeficiency patients.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is another critical application area for gamma globulin therapies, as these treatments have proven effective in managing this debilitating condition. CIDP is characterized by progressive weakness and sensory loss due to damage to the peripheral nerves, which can significantly impact a patient's quality of life. The use of gamma globulin can help modulate the immune response, reducing inflammation and promoting nerve function recovery. As awareness of CIDP increases and more patients receive timely diagnoses, the demand for effective treatment options, including immune globulin therapies, is expected to rise. The ongoing research into new treatment protocols and formulations is anticipated to further bolster the market in this application segment.

Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura (ITP) is a hematological disorder characterized by a low platelet count due to immune-mediated destruction. Gamma globulin therapies are widely used in managing ITP, as they can help increase the platelet count and reduce bleeding risks. The increasing recognition of ITP and the need for effective treatment options have contributed to the growth of this segment within the gamma globulin market. Ongoing clinical trials exploring the efficacy of gamma globulin in different ITP patient populations are expected to lead to expanded indications and improved treatment protocols. The emphasis on personalized medicine and tailored therapies in ITP management is likely to enhance the market's overall prospects.

Guillain-Barré Syndrome

Guillain-Barré Syndrome (GBS) is an autoimmune disorder characterized by rapid-onset muscle weakness and can lead to life-threatening complications. Gamma globulin therapies, particularly IVIG, have been shown to be effective in treating GBS by modulating the immune response and reducing inflammation. The recognition of the role of gamma globulin in GBS management has driven its adoption in clinical practice, resulting in a growing demand for these products. As research continues to elucidate the mechanisms underlying GBS and the efficacy of gamma globulin therapies, the market is expected to see further growth. Increased awareness about GBS among healthcare providers and patients is also contributing to the rising demand for gamma globulin treatments in this application area.

Immunodeficiency Diseases

Immunodeficiency diseases encompass a broad range of disorders characterized by compromised immune function, often leading to increased susceptibility to infections. The gamma globulin market has a significant role in addressing these diseases through the provision of effective therapies that enhance the immune response. The increasing prevalence of various immunodeficiency disorders, including secondary immunodeficiencies due to chronic diseases or therapies, is expected to drive the demand for gamma globulin products. The awareness around preventive healthcare and the importance of immunoglobulin therapy in managing these conditions is helping to solidify the standing of gamma globulin treatments in the healthcare landscape.

Multifocal Motor Neuropathy (MMN)

Multifocal Motor Neuropathy (MMN) is a rare autoimmune disorder leading to progressive muscle weakness and atrophy. Gamma globulin therapy, particularly through the use of IVIG, has been established as an effective treatment option for patients with MMN. The mechanism of action involves the reduction of antibodies that attack the nerve fibers, helping to restore muscle function. As more healthcare providers become aware of MMN and the potential benefits of gamma globulin therapies, the demand for these products is expected to rise. Ongoing research efforts to better understand MMN and its treatment will likely enhance the market for gamma globulin, making it a vital player in the neurological treatment landscape.

By Distribution Channel

Hospitals

The hospital segment remains a significant distribution channel for gamma globulin products, primarily due to the critical need for clinical oversight during administration. Hospitals are equipped with the necessary medical infrastructure and personnel to manage the potential side effects associated with intravenous gamma globulin therapies. This setting is particularly important for patients with complex medical histories or those receiving treatment for serious conditions, such as autoimmune disorders or severe immunodeficiencies. The growing number of hospital admissions for chronic disease management is expected to support the continued demand for gamma globulin products within this channel. Additionally, the availability of specialized clinics within hospitals further enhances the service delivery of gamma globulin therapies, thereby strengthening this distribution channel's role in the market.

Clinics

Clinics, including specialized care facilities focusing on immunology and neurology, are emerging as vital distribution channels for gamma globulin products. These centers often provide targeted therapies, including gamma globulin treatments, for patients with specific conditions such as primary immunodeficiency and neuromuscular disorders. The convenience of receiving treatment in outpatient settings facilitates patient access and adherence to therapy schedules. Additionally, as more clinics adopt innovative patient management strategies and enhance their treatment offerings, the demand for gamma globulin products in this segment is expected to grow. Increased collaboration between hospitals and clinics to streamline patient referrals and treatment pathways will further enhance the market for gamma globulin in clinic settings.

Retail Pharmacies

Retail pharmacies are becoming increasingly important in the distribution of gamma globulin products, particularly subcutaneous immunoglobulin therapies that can be administered at home. This shift towards self-administration is changing the landscape of gamma globulin distribution, making therapies more accessible to patients. Retail pharmacies often have the capability to stock these specialized products and offer patients the necessary education and support for safe administration. The rising trend of personalized medicine and patient-centric care is likely to further bolster the role of retail pharmacies in the gamma globulin market. Additionally, as awareness around the importance of immunotherapy grows, patients are more likely to seek out these products at their local pharmacies, driving demand in this channel.

Online Pharmacies

Online pharmacies are rapidly changing the dynamics of the gamma globulin market by providing patients with greater accessibility to these specialized products. The ability to order gamma globulin therapies online facilitates convenience for patients, particularly those with mobility challenges or those living in remote areas. The COVID-19 pandemic has significantly accelerated the adoption of online pharmacy services, with patients increasingly relying on digital platforms for medication delivery. As telehealth services continue to grow, online pharmacies are likely to play an integral role in providing necessary support, such as consultations and follow-up care, for gamma globulin therapies. This channel's expansion is expected to enhance market growth, particularly among patients seeking easy access to their treatment options.

By Ingredient Type

Polyvalent Immunoglobulin

Polyvalent immunoglobulin is a critical ingredient type in the gamma globulin market, comprising a broad range of antibodies that provide passive immunity against various pathogens. This product is commonly used in the treatment of various immunodeficiency diseases and autoimmune disorders. The versatility of polyvalent immunoglobulin makes it suitable for a wide array of applications, which enhances its market presence. As the understanding of patient-specific needs grows, the demand for polyvalent formulations is likely to continue increasing. Furthermore, advancements in manufacturing technologies that enhance the purity and efficacy of polyvalent immunoglobulin will also contribute positively to its growth trajectory within the gamma globulin market.

Monoclonal Immunoglobulin

Monoclonal immunoglobulin, or monoclonal antibodies, is gaining traction in the gamma globulin market due to their specificity and targeted action against particular antigens. These products are increasingly utilized in the treatment of various diseases, including certain types of cancers and autoimmune disorders. The ability of monoclonal immunoglobulin to provide precise therapeutic benefits is raising interest among healthcare providers and patients alike. Ongoing research and development efforts aimed at producing new monoclonal antibodies with improved efficacy and safety profiles are expected to drive market growth. As personalized medicine continues to gain prominence, the role of monoclonal immunoglobulin in treating complex diseases is likely to expand, further solidifying its significance in the gamma globulin market.

By Region

The regional analysis of the gamma globulin market underscores the dominance of North America, which is anticipated to account for about 40% of the global market share by 2035. Factors such as high healthcare expenditure, advanced healthcare infrastructure, and increasing incidence of immunodeficiency disorders contribute to the region's leading position. The North American market is projected to grow at a CAGR of approximately 9% from 2025 to 2035, driven by the increasing adoption of gamma globulin therapies and ongoing research initiatives aimed at improving treatment protocols. Europe is another key market, accounting for around 30% of the global share. The growth in Europe is largely attributed to the rising awareness of gamma globulin therapies among healthcare providers and patients, as well as supportive government initiatives focused on improving healthcare access and treatment options.

In the Asia Pacific region, the gamma globulin market is experiencing rapid growth, with projections indicating a CAGR of around 10% over the forecast period. The increasing prevalence of chronic diseases, coupled with a growing population and rising healthcare awareness, is driving the demand for immunoglobulin therapies in countries like India, China, and Japan. Latin America and the Middle East & Africa are also expected to contribute to market growth, albeit at a slower pace, as healthcare systems continue to evolve and access to immunotherapy improves. Overall, the regional dynamics of the gamma globulin market are closely tied to healthcare infrastructure, disease prevalence, and patient awareness, which will shape future growth trends.

Opportunities

The gamma globulin market is poised to benefit from several emerging opportunities that can significantly foster its growth. One such opportunity lies in the increasing investment in research and development aimed at innovating new formulations and delivery mechanisms for gamma globulin therapies. Companies are focusing on developing subcutaneous routes of administration that could enable patients to self-administer treatments, thereby improving compliance and convenience. Additionally, as healthcare providers recognize the benefits of individualized treatment approaches, the demand for gamma globulin tailored to specific patient needs is likely to increase. The expansion of clinical trials exploring the efficacy of gamma globulin in diverse health conditions, from autoimmune diseases to infectious diseases, will further enhance the market's potential.

Another promising opportunity is the increasing prevalence of chronic and rare diseases globally, which necessitates effective therapeutic interventions. As awareness around immunodeficiency disorders and their management grows, healthcare providers are more inclined to consider gamma globulin therapies as viable treatment options. Furthermore, the rise in telemedicine and remote healthcare services presents an opportunity for gamma globulin companies to reach patients directly through online consultations and delivery services. This shift towards digital health solutions is creating new pathways for product distribution, enhancing market access, and improving patient outcomes. Consequently, these factors combined present a favorable outlook for growth opportunities within the gamma globulin market.

Threats

Despite the promising growth prospects, the gamma globulin market faces several threats that could impede its progress. One major challenge is the rising cost of production, which may result in increased prices for gamma globulin therapies. The complexity of manufacturing processes, coupled with stringent regulations governing product quality and safety, contributes to these costs. Consequently, higher prices can restrict patient access to essential treatments, particularly in lower-income regions or among uninsured populations. Additionally, the emergence of alternative therapies, including monoclonal antibodies and other immunomodulators, poses a competitive threat, potentially diverting attention away from traditional gamma globulin therapies.

Moreover, safety concerns related to gamma globulin therapies, such as potential adverse effects and allergic reactions, may discourage some healthcare providers from prescribing these treatments. Although regulatory agencies conduct rigorous evaluations to ensure product safety, any negative publicity stemming from adverse events can impact public perception and trust in gamma globulin therapies. Furthermore, the market may face challenges related to supply chain disruptions, which could arise from global events such as pandemics or geopolitical tensions. These disruptions can hinder the availability of gamma globulin products and threaten the overall stability of the market.

Competitor Outlook

• Grifols, S.A.
• Shire (Takeda Pharmaceutical Company Limited)
• Octapharma AG
• CSL Behring
• Baxter International Inc.
• Bio Products Laboratory Ltd.
• Kedrion S.p.A.
• Hualan Biological Engineering Inc.
• LFB S.A.
• Emergent BioSolutions Inc.
• Fresenius Kabi AG
• Samsung Biologics
• Janssen Biotech, Inc.
• ADMA Biologics, Inc.
• Argenx SE

The competitive landscape of the gamma globulin market is characterized by the presence of several leading companies that are continually innovating to gain market share. Major players such as Grifols, S.A. and CSL Behring are recognized for their extensive product lines and commitment to quality, offering a variety of gamma globulin formulations to cater to diverse patient needs. Grifols, for instance, has established a strong presence in the market through its emphasis on research and development, which facilitates the introduction of new and improved products. The company also maintains strategic partnerships with healthcare providers to enhance patient access to its therapies.

Takeda Pharmaceutical Company, through its Shire division, is also a significant competitor, focusing on developing specialized therapies for rare diseases, including immunodeficiencies and autoimmune conditions. The company’s global reach and robust pipeline of gamma globulin products position it well to capitalize on market growth opportunities. Similarly, Octapharma AG is known for its dedication to producing high-quality immunoglobulin therapies, emphasizing patient safety and effective treatment outcomes. The company’s commitment to sustainability and innovation in manufacturing processes further enhances its competitive advantage in the market.

Other companies, such as Baxter International and Emergent BioSolutions, are also leveraging advanced manufacturing technologies and research initiatives to diversify their product offerings. Baxter, in particular, emphasizes the importance of collaboration with healthcare providers and patients to optimize treatment protocols and improve patient education around gamma globulin therapies. As competition in the market intensifies, these companies are expected to prioritize strategic acquisitions and partnerships, enhancing their capabilities and expanding their market reach.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 LFB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Argenx SE
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CSL Behring
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Grifols, S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Octapharma AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Kedrion S.p.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Fresenius Kabi AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Samsung Biologics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 ADMA Biologics, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Janssen Biotech, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Baxter International Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Emergent BioSolutions Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bio Products Laboratory Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hualan Biological Engineering Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shire (Takeda Pharmaceutical Company Limited)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Gamma Globulin Market, By Application
    • 6.1.1 Primary Immunodeficiency
    • 6.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 6.1.3 Immune Thrombocytopenic Purpura (ITP)
    • 6.1.4 Guillain-Barré Syndrome
    • 6.1.5 Immunodeficiency Diseases
    • 6.1.6 Multifocal Motor Neuropathy (MMN)
  • 6.2 Gamma Globulin Market, By Product Type
    • 6.2.1 Immune Globulin Intravenous (IGIV)
    • 6.2.2 Immune Globulin Subcutaneous (IGSC)
    • 6.2.3 Hyperimmune Globulin
  • 6.3 Gamma Globulin Market, By Ingredient Type
    • 6.3.1 Polyvalent Immunoglobulin
    • 6.3.2 Monoclonal Immunoglobulin
  • 6.4 Gamma Globulin Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Gamma Globulin Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Gamma Globulin market is categorized based on

By Product Type

• Immune Globulin Intravenous (IGIV)
• Immune Globulin Subcutaneous (IGSC)
• Hyperimmune Globulin

By Application

• Primary Immunodeficiency
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Immune Thrombocytopenic Purpura (ITP)
• Guillain-Barré Syndrome
• Immunodeficiency Diseases
• Multifocal Motor Neuropathy (MMN)

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Polyvalent Immunoglobulin
• Monoclonal Immunoglobulin

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Grifols, S.A.
• Shire (Takeda Pharmaceutical Company Limited)
• Octapharma AG
• CSL Behring
• Baxter International Inc.
• Bio Products Laboratory Ltd.
• Kedrion S.p.A.
• Hualan Biological Engineering Inc.
• LFB S.A.
• Emergent BioSolutions Inc.
• Fresenius Kabi AG
• Samsung Biologics
• Janssen Biotech, Inc.
• ADMA Biologics, Inc.
• Argenx SE